α ‐Hydroxybutyrate Association With Incident Type 2 Diabetes Over 10 Years Across Different Glycemic States
Authors' conclusion
Plasma α-HB is a robust, independent risk marker of incident T2DM over a decade, which identifies long-term metabolic risk not fully captured by glycaemic status alone.
Study context
- Population
- Participants without known diabetes from the Swedish PAROKRANK study, categorised by 2-h OGTT as normoglycemia, impaired fasting glucose, impaired glucose tolerance or T2D
- Participants
- 1,349 participants
- Exposure
- Per unit increase in log-transformed plasma α-HB
- Outcome
- Incident T2D identified via national registries
- Follow-up
- 9.95-year median
Main finding
As reported in the abstract
Incident T2D per unit increase in log-transformed α-HB
Per unit increase in log-transformed α-HBHazard ratio (95% CI)
Univariate analysis
1.99(1.32–3.01)
Adjusted for clinical variables incl. BMI and fasting HbA1c
1.78(1.19–2.67)
Per unit increase in log-transformed α-HB, as printed
- Developed T2D during follow-up
- 134 (11%)
Observational data: associations, not effects.
Further findings
Reclassification: addition of α-HB to a clinical model
- Category-less Net Reclassification Improvement (NRI) improvement (p = 0.01)
- 0.23
Baseline α-HB across glycemic states
- α-HB levels showed a stepwise elevation across the spectrum of dysglycemia
Original publication
α ‐Hydroxybutyrate Association With Incident Type 2 Diabetes Over 10 Years Across Different Glycemic States. Diabetes Obes Metab. Published 2 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →